These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 28159767

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Factor XIII and tranexamic acid but not recombinant factor VIIa attenuate tissue plasminogen activator-induced hyperfibrinolysis in human whole blood.
    Dirkmann D, Görlinger K, Gisbertz C, Dusse F, Peters J.
    Anesth Analg; 2012 Jun; 114(6):1182-8. PubMed ID: 22104068
    [Abstract] [Full Text] [Related]

  • 3. Combination of recombinant factor VIIa and fibrinogen corrects clot formation in primary immune thrombocytopenia at very low platelet counts.
    Larsen OH, Stentoft J, Radia D, Ingerslev J, Sørensen B.
    Br J Haematol; 2013 Jan; 160(2):228-36. PubMed ID: 23151086
    [Abstract] [Full Text] [Related]

  • 4. In vitro effects of recombinant activated factor VII on thrombin generation and coagulation following inhibition of platelet procoagulant activity by prasugrel.
    Mazzeffi M, Szlam F, Jakubowski JA, Tanaka KA, Sugidachi A, Levy JH.
    Thromb Res; 2013 Jul; 132(1):106-11. PubMed ID: 23664633
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Recombinant GPVI-Fc added to single or dual antiplatelet therapy in vitro prevents plaque-induced platelet thrombus formation.
    Mojica Muñoz AK, Jamasbi J, Uhland K, Degen H, Münch G, Ungerer M, Brandl R, Megens R, Weber C, Lorenz R, Siess W.
    Thromb Haemost; 2017 Aug 01; 117(8):1651-1659. PubMed ID: 28569920
    [Abstract] [Full Text] [Related]

  • 10. Multimodal assessment of non-specific hemostatic agents for apixaban reversal.
    Martin AC, Gouin-Thibault I, Siguret V, Mordohay A, Samama CM, Gaussem P, Le Bonniec B, Godier A.
    J Thromb Haemost; 2015 Mar 01; 13(3):426-36. PubMed ID: 25630710
    [Abstract] [Full Text] [Related]

  • 11. An in vitro study of the effects of t-PA and tranexamic acid on whole blood coagulation and fibrinolysis.
    Godier A, Parmar K, Manandhar K, Hunt BJ.
    J Clin Pathol; 2017 Feb 01; 70(2):154-161. PubMed ID: 27445340
    [Abstract] [Full Text] [Related]

  • 12. Recombinant factor VIIa and fibrinogen display additive effect during in vitro haemodilution with crystalloids.
    Fenger-Eriksen C, Tønnesen E, Ingerslev J, Sørensen B.
    Acta Anaesthesiol Scand; 2009 Mar 01; 53(3):332-8. PubMed ID: 19243319
    [Abstract] [Full Text] [Related]

  • 13. Fibrinogen depletion after plasma-dilution: impairment of proteolytic resistance and reversal via clotting factor concentrates.
    He S, Johnsson H, Zabczyk M, Hultenby K, Wallén H, Blombäck M.
    Thromb Haemost; 2014 Mar 03; 111(3):417-28. PubMed ID: 24196490
    [Abstract] [Full Text] [Related]

  • 14. Reversal of clopidogrel-induced bleeding with rFVIIa in healthy subjects: a randomized, placebo-controlled, double-blind, exploratory study.
    Skolnick BE, Shenouda M, Khutoryansky NM, Pusateri AE, Gabriel D, Carr ME.
    Anesth Analg; 2011 Oct 03; 113(4):703-10. PubMed ID: 21890888
    [Abstract] [Full Text] [Related]

  • 15. Rational and timely haemostatic interventions following cardiac surgery - coagulation factor concentrates or blood bank products.
    Tang M, Fenger-Eriksen C, Wierup P, Greisen J, Ingerslev J, Hjortdal V, Sørensen B.
    Thromb Res; 2017 Jun 03; 154():73-79. PubMed ID: 28437748
    [Abstract] [Full Text] [Related]

  • 16. The in vitro effect of recombinant factor VIIa on coated platelet formation and clot dynamics of stored platelet concentrates.
    Svendsen MS, Kristensen AT, Bochsen L, Salado-Jimena JA, Johansson PI.
    Transfusion; 2009 Oct 03; 49(10):2186-94. PubMed ID: 19527478
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis.
    Martin AC, Le Bonniec B, Fischer AM, Marchand-Leroux C, Gaussem P, Samama CM, Godier A.
    Int J Cardiol; 2013 Oct 09; 168(4):4228-33. PubMed ID: 23928345
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of recombinant factor VIIa, tranexamic acid and desmopressin to reduce prasugrel-related bleeding: A randomised, placebo-controlled study in a rabbit model.
    Bonhomme F, Lecompte T, Samama CM, Godier A, Fontana P.
    Eur J Anaesthesiol; 2018 Mar 09; 35(3):208-214. PubMed ID: 29334511
    [Abstract] [Full Text] [Related]

  • 19. The in vivo effect of fibrinogen and factor XIII on clot formation and fibrinolysis in Glanzmann's thrombasthenia.
    Shenkman B, Livnat T, Misgav M, Budnik I, Einav Y, Martinowitz U.
    Platelets; 2012 Mar 09; 23(8):604-10. PubMed ID: 22273510
    [Abstract] [Full Text] [Related]

  • 20. Factor VIIa analog has marked effects on platelet function and clot kinetics in blood from patients with hemophilia A.
    Brophy DF, Martin EJ, Nolte ME, Kuhn JG, Barrett JC, Ezban M.
    Blood Coagul Fibrinolysis; 2010 Sep 09; 21(6):539-46. PubMed ID: 20581663
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.